{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'Signature Page -Coordinating Investigator', 'Study Title:', 'A Phase IV, prospective, multicenter, open label,', 'uncontrolled, non-interventional, single arm study to', 'measure treatment satisfaction of multiple sclerosis', '(MS) patients on Rebif after discontinuing initial first-', 'line treatment', 'Study Protocol Date / Version:', '10 Oct 2016 / Version 2.0', '1 approve the design of the non-interventional study and 1 understand and will conduct the study', 'according to the study protocol, any approved protocol amendments, Good Pharmaco-', 'epidemiology Practices (GPP) and all applicable Health Authority requirements and national', 'laws.', 'Signature', 'Date of Signature', 'PPD', 'Name, academic degree:', 'Function / Title:', 'Institution:', 'Address:', 'Telephone number:', 'Fax number:', 'E-mail address:', 'PPD', 'CONFIDENTIAL', '59/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'Signature Page - Principal Investigator', 'Study Title', 'A Phase IV, prospective, multicenter, open label,', 'uncontrolled, non-interventional, single arm study to', 'measure treatment satisfaction of multiple sclerosis', '(MS) patients on Rebif after discontinuing initial', 'first-line treatment', 'Study Protocol Date / Version', '07 Oct 2016 / Version 2.0', 'Center Number', 'Principal Investigator', 'I, the undersigned, am responsible for the conduct of the study at this site and affirm that I', 'understand and will conduct the study according to the study protocol, any approved protocol', 'amendments, Good Pharmaco-epidemiology Practices (GPP) and all applicable Health Authority', 'requirements and national laws.', 'Signature', 'Date of Signature', 'Name, academic degree:', 'Function / Title:', 'Institution:', 'Address:', 'Telephone number:', 'Fax number:', 'E-mail address:', 'CONFIDENTIAL', '60/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}